Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

mplied discussions regarding the potential development and marketing of potential future respiratory products, regarding potential future launches of indacaterol, or regarding potential future revenues from indacaterol. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis will successfully develop or bring to market any additional respiratory products.  Nor can there be any guarantee that indacaterol will be launched in any particular countries, or at any particular time.  Neither can there be any guarantee that indacaterol will achieve any particular levels of revenue in the future. In particular, management's expectations regarding indacaterol could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including unexpected reimbursement difficulties or delays; competition in general; government, industry and general public pricing pressures; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... VG Energy, a subsidiary of Viral Genetics, Inc. ... that it has retained alternative energy producer BioProcess ... for the development of commercial production of its potential ... with results reproduced multiple times from test-tube to small-pond ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... for the District of Delaware has ruled that Watson,s ... United States Patent No. 6,264,981 (the ,981 Patent).  The ... and would evaluate all available options, including an appeal. ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... proliferation of endogenous neural precursor cells cannot alone ... From the perspective of neural plasticity, Dr. Yun ... China observed the effects of functional electrical stimulation ... expression of basic fibroblast growth factor and epidermal ... infarct side. The researchers found that functional electrical ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... (XMRV) has been the subject of many studies since ... an unclear picture of XMRV,s role in human disease. ... issue of The Journal of Infectious Diseases , ... between XMRV and prostate cancer but not other links ...
... TUESDAY, Oct. 12 (HealthDay News) -- Women who maintain certain ... if a close relative has had the disease, a new ... healthy weight and drinking alcohol in moderation, if at all, ... breast cancer in postmenopausal women, the researchers said. "Whether ...
... Phase-II trial investigating a new, targeted therapy for metastatic ... reported at the 35th Congress of the European Society ... cancers affect the tissue lining the inner surfaces of ... In cases of metastatic disease, median survival is approximately ...
... can lead some women to wonder if the risk is ... 85,000 postmenopausal women, published in BioMed Central,s open access journal ... maintaining a healthy weight, and drinking less alcohol lowers breast ... of the disease. The University of Rochester Medical Center ...
... Gardner HealthDay Reporter , MONDAY, Oct. 11 ... in a U.S.-government-approved study involving human embryonic stem cells ... saving cells. The patient, being cared for at ... a spinal cord injury. The center specializes in treating ...
... lead some people to wonder if their risk is out ... postmenopausal women observed that regular physical activity, maintaining a healthy ... women with, and without a family history of the disease. ... Oct. 12, 2010, by the journal Breast Cancer Research ...
Cached Medicine News:Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Three Healthy Habits Cut Breast Cancer Risk, Study Finds 2Health News:Three Healthy Habits Cut Breast Cancer Risk, Study Finds 3Health News:Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2
... Massive hemorrhage associated with displaced pelvic fractures ... faced by orthopaedic and trauma surgeons. , ... antishock garment, external fixation, and internal fixation ... Stabilizer has been developed as a method ...
The large External Fixator consists of rods, clamps, and pins. It has multiple external fixation frames, independent pin placement, and MR safe clamps. The modular frame construction permits fracture...
The DFS Standard Fixator advantages include a highly adjustable system, modular compression/distraction, versatile central body component that provides 360 of rotation, and a positive locking mechani...
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: